BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10792993)

  • 1. HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation.
    Okamoto H; Cujec TP; Peterlin BM; Okamoto T
    Virology; 2000 May; 270(2):337-44. PubMed ID: 10792993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37.
    Okamoto H; Cujec TP; Okamoto M; Peterlin BM; Baba M; Okamoto T
    Virology; 2000 Jul; 272(2):402-8. PubMed ID: 10873784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
    Kashanchi F; Sadaie MR; Brady JN
    Virology; 1997 Jan; 227(2):431-8. PubMed ID: 9018142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator.
    Marcello A; Zoppé M; Giacca M
    IUBMB Life; 2001 Mar; 51(3):175-81. PubMed ID: 11547919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.
    Desfosses Y; Solis M; Sun Q; Grandvaux N; Van Lint C; Burny A; Gatignol A; Wainberg MA; Lin R; Hiscott J
    J Virol; 2005 Jul; 79(14):9180-91. PubMed ID: 15994812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b.
    Wimmer J; Fujinaga K; Taube R; Cujec TP; Zhu Y; Peng J; Price DH; Peterlin BM
    Virology; 1999 Mar; 255(1):182-9. PubMed ID: 10049833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tat mediates transcriptional activation of HIV-1 gene in vitro.
    West M; Hoover T; Kung H; Raziuddin
    Indian J Biochem Biophys; 1995 Dec; 32(6):351-5. PubMed ID: 8714203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of the RAP74 subunit of TFIIF correlates with Tat-activated transcription of the HIV-1 long terminal repeat.
    Zhou M; Kashanchi F; Jiang H; Ge H; Brady JN
    Virology; 2000 Mar; 268(2):452-60. PubMed ID: 10704353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication.
    Accolla RS; Mazza S; De Lerma Barbaro A; De Maria A; Tosi G
    Eur J Immunol; 2002 Oct; 32(10):2783-91. PubMed ID: 12355430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine.
    Jiang MC; Lin JK; Chen SS
    Biochem Biophys Res Commun; 1996 Sep; 226(1):1-7. PubMed ID: 8806583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication.
    Verhoef K; Koper M; Berkhout B
    Virology; 1997 Oct; 237(2):228-36. PubMed ID: 9356335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator.
    Roof P; Ricci M; Genin P; Montano MA; Essex M; Wainberg MA; Gatignol A; Hiscott J
    Virology; 2002 Apr; 296(1):77-83. PubMed ID: 12036319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication.
    McAllister JJ; Phillips D; Millhouse S; Conner J; Hogan T; Ross HL; Wigdahl B
    Virology; 2000 Sep; 274(2):262-77. PubMed ID: 10964770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Tat in HIV-1 replication: an activator and/or a suppressor?
    Liang C; Wainberg MA
    AIDS Rev; 2002; 4(1):41-9. PubMed ID: 11998784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.
    Demirhan I; Chandra A; Sarin PS; Hasselmayer O; Hofmann D; Chandra P
    Anticancer Res; 2000; 20(4):2513-7. PubMed ID: 10953320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular approaches to inhibit HIV-1 tat expression and functions.
    Grossi MP; Caputo A; Zucchini S; Bozzini R; Marconi PC; Manservigi R; Barbanti-Brodano G; Balboni PG
    Year Immunol; 1993; 7():199-204. PubMed ID: 8396820
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV-1 Tat: coping with negative elongation factors.
    Garber ME; Jones KA
    Curr Opin Immunol; 1999 Aug; 11(4):460-5. PubMed ID: 10448148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H. saimiri tyrosine-kinase interacting protein inhibits Tat function: a prototypic strategy for restricting HIV-1-induced cytopathic effects in immune cells.
    Raymond AD; Hasham M; Tsygankov AY; Henderson EE
    Virology; 2006 Sep; 352(2):253-67. PubMed ID: 16780912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of the HIV-1 Tat and RAP74 proteins with the RNA polymerase II CTD phosphatase FCP1.
    Abbott KL; Archambault J; Xiao H; Nguyen BD; Roeder RG; Greenblatt J; Omichinski JG; Legault P
    Biochemistry; 2005 Mar; 44(8):2716-31. PubMed ID: 15723517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin T1 stabilizes expression levels of HIV-1 Tat in cells.
    Imai K; Asamitsu K; Victoriano AF; Cueno ME; Fujinaga K; Okamoto T
    FEBS J; 2009 Dec; 276(23):7124-33. PubMed ID: 20064163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.